Top Cited Papers
Open Access
Abstract
The echinocandins represent the first new antifungal drug class introduced for more than 15 years. They inhibit the synthesis of β-d-glucan in fungal cell walls. Their strengths include low toxicity, rapid fungicidal activity against most isolates of Candida spp. and predictable favourable kinetics allowing once a day dosing. In addition to Candida spp., their inhibitory spectrum includes Aspergillus spp. and Pneumocystis carinii, but not Cryptococcus neoformans.

This publication has 0 references indexed in Scilit: